Novel synergistic drug combinations proposed for pediatric T cell leukemia
Researchers from Erasmus Medical Center and NTRC have discovered novel combinations of experimental small molecule drugs that synergistically block pathologic activation of the IL7-receptor signalling cascade in leukemic cells of pediatric T-cell acute lymphoblastic leukemic (T-ALL) patients.
Read more
Oncodrugs – Samen op zoek naar nieuwe geneesmiddelen
Doel van het project Oncodrugs is om gezamenlijk kansrijke werkzame stoffen te vinden die vervolgens ontwikkeld kunnen worden tot oncologische geneesmiddelen.
Read more
Pivot Park behaalt COCi status
Per 7 maart heeft Pivot Park de status Center for Open Chemical Innovation (COCi). Deze titel, uitgegeven door Topsector Chemie, geeft aan dat Pivot Park een geschikte vestigingslocatie is voor innoverende ondernemers.
Read more
BioConnection Opens Manufacturing Plant in Oss
BioConnection, Contract Development and Manufacturing Organization, has opened today its manufacturing plant in Oss.
Read more
AstraZeneca enhances long-term growth through Oncology investment in Acerta Pharma
AstraZeneca today announced that it has entered into an agreement to invest in Acerta Pharma.
Read more
NTRC has identified IDO1 inhibitors with best-in-class properties
NTRC today announced that they have identified a series of IDO1 inhibitors with best-in-class properties by screening at the European Lead Factory.
Read more
NTRC and Vipergen receive Eurostars support for cancer immunotherapy research
NTRC and Vipergen ApS announced that they have received support for their research on the identification of novel drug candidates for cancer immunotherapy.
Read more
Aduro Biotech Establishes European Subsidiary
Aduro Biotech, Inc. (Nasdaq:ADRO) has established European subsidiary headquarters at the BioNovion site in Oss.
Read more
Article Dutch Life Sciences – Pivot Park: top-class research facilities for all
Dutch Life Sciences Conference interviews Mirjam Mol and Gerjan Kemperman.
Read more